Global Novel Oral AntiCoagulants (NOAC) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Novel Oral AntiCoagulants (NOAC) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.
Novel Oral AntiCoagulants (NOAC) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Novel Oral AntiCoagulants (NOAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Deep Vein Thrombosis (DVT) and Pulmonary Embolism are the major drivers for the industry.
Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.
North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Novel Oral AntiCoagulants (NOAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Novel Oral AntiCoagulants (NOAC) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Novel Oral AntiCoagulants (NOAC), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Novel Oral AntiCoagulants (NOAC) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Novel Oral AntiCoagulants (NOAC) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Novel Oral AntiCoagulants (NOAC) introduction, etc. Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Novel Oral AntiCoagulants (NOAC) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Novel Oral AntiCoagulants (NOAC) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Novel Oral AntiCoagulants (NOAC) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Deep Vein Thrombosis (DVT) and Pulmonary Embolism are the major drivers for the industry.
Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.
North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Novel Oral AntiCoagulants (NOAC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Segment by Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Novel Oral AntiCoagulants (NOAC) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Novel Oral AntiCoagulants (NOAC), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Novel Oral AntiCoagulants (NOAC) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Novel Oral AntiCoagulants (NOAC) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Novel Oral AntiCoagulants (NOAC) introduction, etc. Novel Oral AntiCoagulants (NOAC) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Novel Oral AntiCoagulants (NOAC) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices